Drug Utilisation of Mysimba/Contrave
NCT06089824 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43324
Last updated 2023-10-18
Summary
This study will assess a retrospective cohort of users of Mysimba/Contrave with up to 548 days (\~18 months) after initiation with treatment with Mysimba/Contrave. This study will describe Mysimba/Contrave utilisation and incidence of AESIs for users compliant and non-compliant with the SmPC.
Conditions
Sponsors & Collaborators
-
Currax Pharmaceuticals
lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-09-30
- Primary Completion
- 2022-10-31
- Completion
- 2022-10-31
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
NCT00392925 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program.
NCT04589130 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
NCT00402077 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY3841136 in Healthy and Overweight Participants
NCT05295940 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06047548 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
NCT00112021 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of LY3502970 in Healthy Overweight and Obese Participants
NCT05313802 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT06525935 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects
NCT00785408 ·Status: COMPLETED ·Phase: PHASE2
-
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
NCT06862791 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Open-Label Extension Study of Setmelanotide
NCT06596135 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
NCT06144684 ·Status: COMPLETED ·Phase: PHASE1
-
Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
NCT00472836 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
NCT00189514 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
NCT06683508 ·Status: COMPLETED ·Phase: PHASE2
-
Examination of the Safety and Tolerability of NNC 0070-0002-0349 in Overweight/Obese Volunteers
NCT00728455 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
NCT06577090 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet
NCT05429593 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
NCT00673387 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
NCT05925920 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity
NCT02835235 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)
NCT05351164 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
NCT03095807 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers
NCT02431442 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
NCT07081958 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2